Star Source Multi Trade Ltd (506365)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Star Source's revenue was ₹0.1 Cr, and net profit ₹0.0 Cr (against a loss a year earlier); the operating margin was 28.4%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹0.1 | — | — |
| Operating profit | ₹0.0 | from loss | from loss |
| Net profit | ₹0.0 | from loss | from loss |
| EPS (₹) | 0.14 | from loss | from loss |
| Operating margin | 28.4% | — | — |
📢 Recent Corporate Announcements
Star Source Multi Trade Limited has scheduled a meeting of its Board of Directors on Tuesday, September 01, 2026. The board will consider and approve the notice of the Annual General Meeting for the financial year ended March 31, 2026. Additionally, the board will determine the book closure dates, record date, and appoint a scrutinizer for the AGM. This is a routine administrative filing with no operational or financial impact.
- Board meeting scheduled for Tuesday, September 01, 2026
- Agenda includes approval of the Annual General Meeting notice for FY ended March 31, 2026
- Board to fix Book Closure and Record Date for the upcoming AGM
- Appointment of Scrutinizer for the forthcoming AGM to be considered
Star Source Multi Trade Ltd (formerly Chemo Pharma Laboratories) reported a marginal net profit of Rs 2.10 Lakhs for the quarter ended June 30, 2026, marking a turnaround from a massive loss of Rs 11.81 Cr in the same quarter last year. Revenue for the quarter stood at Rs 7.46 Lakhs, compared to zero revenue in both the preceding quarter (March 2026) and the year-ago quarter (June 2025). The company's total expenditure was drastically reduced to Rs 5.36 Lakhs from Rs 11.83 Cr YoY, primarily due to the absence of large 'Other Expenses' that plagued previous periods. Despite the turnaround, the company remains a micro-cap with a market capitalization of just Rs 12 Cr and negative reserves of Rs 2.02 Cr.
- Net Profit of Rs 2.10 Lakhs in Q1 FY27 vs a loss of Rs 11.81 Cr in Q1 FY26.
- Net Sales reached Rs 7.46 Lakhs in Q1 FY27, up from zero revenue in the previous quarter.
- Total Expenditure decreased by 99.5% YoY to Rs 5.36 Lakhs from Rs 118.26 Cr (in thousands).
- Earnings Per Share (EPS) turned positive at Rs 0.14 compared to -Rs 78.70 in the year-ago period.
- Negative Reserves stood at Rs 2.02 Cr as of June 30, 2026.
Star Source Multi Trade Ltd (formerly Chemo Pharma Laboratories) reported a marginal net profit of ₹2.10 Lakhs for Q1 FY27, a significant recovery from a loss of ₹11.81 Crore in Q1 FY26. Revenue for the quarter reached ₹7.46 Lakhs, compared to zero revenue in both the previous quarter (Mar 2026) and the year-ago quarter (Jun 2025). The turnaround is primarily driven by a massive reduction in 'Other Expenses,' which fell from ₹1,180.12 Lakhs to just ₹2.46 Lakhs YoY. While the return to profitability is positive, the company's operational scale remains extremely small relative to its ₹12 Crore market capitalization.
- Net Profit of ₹2.10 Lakhs in Q1 FY27 vs a loss of ₹1,180.51 Lakhs in Q1 FY26
- Revenue from operations rose to ₹7.46 Lakhs from zero in the sequential quarter (Mar 2026)
- Total expenditure plummeted to ₹5.36 Lakhs from ₹1,182.58 Lakhs in the year-ago period
- Basic EPS improved to ₹0.14 from a negative ₹78.70 in June 2025
- Other Expenses reduced by 99.7% YoY to ₹2.46 Lakhs
Star Source Multi Trade Ltd has scheduled a board meeting for August 14, 2026, to approve unaudited financial results for the quarter ended June 30, 2026. The company is currently in a stressed financial state, reporting a TTM net loss of ₹12 crore on a minimal revenue of ₹1 crore. Notably, the company reported zero revenue in the two most recent quarters (December 2025 and March 2026). With a market cap of only ₹12 crore and a negative ROCE of -164%, the upcoming results are critical for assessing operational viability.
- Board meeting scheduled for August 14, 2026, to approve Q1 FY27 results.
- Trading window for designated persons has been closed since July 01, 2026.
- Company reported a significant TTM net loss of ₹12 crore.
- Revenue for the most recent quarter (March 2026) was ₹0.0 crore.
- Stock has seen a 12-month price return of -45.6%.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
